131 related articles for article (PubMed ID: 11137708)
21. 1-[N, O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4- phenylpiperazine (KN-62), an inhibitor of calcium-dependent camodulin protein kinase II, inhibits both insulin- and hypoxia-stimulated glucose transport in skeletal muscle.
Brozinick JT; Reynolds TH; Dean D; Cartee G; Cushman SW
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):533-40. PubMed ID: 10215590
[TBL] [Abstract][Full Text] [Related]
22. Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.
Eymin B; Dubrez L; Allouche M; Solary E
Cancer Res; 1997 Feb; 57(4):686-95. PubMed ID: 9044846
[TBL] [Abstract][Full Text] [Related]
23. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line.
Reuveni D; Halperin D; Shalit I; Priel E; Fabian I
Int J Oncol; 2010 Aug; 37(2):463-71. PubMed ID: 20596674
[TBL] [Abstract][Full Text] [Related]
24. The effect of KN-62, Ca2+/calmodulin dependent protein kinase II inhibitor on cell cycle.
Minami H; Inoue S; Hidaka H
Biochem Biophys Res Commun; 1994 Feb; 199(1):241-8. PubMed ID: 8123019
[TBL] [Abstract][Full Text] [Related]
25. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
[TBL] [Abstract][Full Text] [Related]
26. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of calmodulin-dependent protein kinase are nonspecific blockers of voltage-dependent K+ channels in vascular myocytes.
Ledoux J; Chartier D; Leblanc N
J Pharmacol Exp Ther; 1999 Sep; 290(3):1165-74. PubMed ID: 10454491
[TBL] [Abstract][Full Text] [Related]
29. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
[TBL] [Abstract][Full Text] [Related]
30. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
[TBL] [Abstract][Full Text] [Related]
31. Relationship between cell cycle changes and variations of the mitochondrial membrane potential induced by etoposide.
Facompré M; Wattez N; Kluza J; Lansiaux A; Bailly C
Mol Cell Biol Res Commun; 2000 Jul; 4(1):37-42. PubMed ID: 11152626
[TBL] [Abstract][Full Text] [Related]
32. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
33. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms intrinsic to 5-HT2B receptor-induced potentiation of NMDA receptor responses in frog motoneurones.
Holohean AM; Hackman JC
Br J Pharmacol; 2004 Oct; 143(3):351-60. PubMed ID: 15339859
[TBL] [Abstract][Full Text] [Related]
35. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
36. Effect of KN-62, Ca2+/calmodulin-dependent protein kinase II inhibitor, on adriamycin resistance of human ovarian cancer cells.
Obata NH; Okazaki K; Maeda O; Kikkawa F; Tomoda Y; Hidaka H
Biochem Biophys Res Commun; 1995 Oct; 215(2):566-71. PubMed ID: 7487993
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16).
Tronov VA; Konoplyannikov MA; Nikolskaya TA; Konstantinov EM
Biochemistry (Mosc); 1999 Mar; 64(3):345-52. PubMed ID: 10205305
[TBL] [Abstract][Full Text] [Related]
38. The histamine H1 receptor in GT1-7 neuronal cells is regulated by calcium influx and KN-62, a putative inhibitor of calcium/calmodulin protein kinase II.
Zamani MR; Bristow DR
Br J Pharmacol; 1996 Jul; 118(5):1119-26. PubMed ID: 8818334
[TBL] [Abstract][Full Text] [Related]
39. [Synergetic cytotoxicity of cisplatin and etoposide to leukemia cell line K562 and its mechanism].
Ma WD; Yin MY; Jiang CW; Xu SR; Zhai LD; Zheng LF; Wang YL; Yan YL
Ai Zheng; 2005 Aug; 24(8):958-64. PubMed ID: 16086873
[TBL] [Abstract][Full Text] [Related]
40. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
